---
document_datetime: 2025-11-23 08:06:34
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vistide.html
document_name: vistide.html
version: success
processing_time: 0.1093581
conversion_datetime: 2025-12-24 16:36:31.866875
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vistide

[RSS](/en/individual-human-medicine.xml/66742)

##### Withdrawn

This medicine's authorisation has been withdrawn

cidofovir

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vistide](#news-on)
- [More information on Vistide](#more-information-on-vistide-1410)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 22 August 2014, the European Commission withdrew the marketing authorisation for Vistide (cidofovir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Gilead Sciences International Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product.

Vistide was granted marketing authorisation in the EU on 23 April 1997 for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2007. Due to manufacturing problems the product had been in short supply in the EU since February 2013. During the shortage, healthcare professionals used alternative medicinal products and generic medicine containing cidofovir. Due to ongoing manufacturing challenges as well as a decreasing incidence of CMV retinitis in adults with AIDS, Gilead Sciences International Ltd decided to request the withdrawal of the marketing authorisation for Vistide.

The European Public Assessment Report (EPAR) for Vistide is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Vistide : EPAR - Summary for the public

English (EN) (500.99 KB - PDF)

**First published:** 27/01/2009

**Last updated:** 19/01/2015

[View](/en/documents/overview/vistide-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-370)

български (BG) (683.27 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/bg/documents/overview/vistide-epar-summary-public_bg.pdf)

español (ES) (510.76 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/es/documents/overview/vistide-epar-summary-public_es.pdf)

čeština (CS) (651.25 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/cs/documents/overview/vistide-epar-summary-public_cs.pdf)

dansk (DA) (510.55 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/da/documents/overview/vistide-epar-summary-public_da.pdf)

Deutsch (DE) (49.8 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/de/documents/overview/vistide-epar-summary-public_de.pdf)

eesti keel (ET) (509.68 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/et/documents/overview/vistide-epar-summary-public_et.pdf)

ελληνικά (EL) (678.89 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/el/documents/overview/vistide-epar-summary-public_el.pdf)

français (FR) (46.78 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/fr/documents/overview/vistide-epar-summary-public_fr.pdf)

italiano (IT) (510.89 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/it/documents/overview/vistide-epar-summary-public_it.pdf)

latviešu valoda (LV) (657.69 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/lv/documents/overview/vistide-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (624.07 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/lt/documents/overview/vistide-epar-summary-public_lt.pdf)

magyar (HU) (642.89 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/hu/documents/overview/vistide-epar-summary-public_hu.pdf)

Malti (MT) (656.55 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/mt/documents/overview/vistide-epar-summary-public_mt.pdf)

Nederlands (NL) (511.31 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/nl/documents/overview/vistide-epar-summary-public_nl.pdf)

polski (PL) (661.08 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/pl/documents/overview/vistide-epar-summary-public_pl.pdf)

português (PT) (511.02 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/pt/documents/overview/vistide-epar-summary-public_pt.pdf)

română (RO) (619.12 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/ro/documents/overview/vistide-epar-summary-public_ro.pdf)

slovenčina (SK) (648.86 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/sk/documents/overview/vistide-epar-summary-public_sk.pdf)

slovenščina (SL) (639.31 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/sl/documents/overview/vistide-epar-summary-public_sl.pdf)

Suomi (FI) (48.65 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/fi/documents/overview/vistide-epar-summary-public_fi.pdf)

svenska (SV) (510.09 KB - PDF)

**First published:**

27/01/2009

**Last updated:**

19/01/2015

[View](/sv/documents/overview/vistide-epar-summary-public_sv.pdf)

## Product information

Vistide : EPAR - Product Information

English (EN) (839.25 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 19/01/2015

[View](/en/documents/product-information/vistide-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-863)

български (BG) (1.63 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/bg/documents/product-information/vistide-epar-product-information_bg.pdf)

español (ES) (851.78 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/es/documents/product-information/vistide-epar-product-information_es.pdf)

čeština (CS) (1.32 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/cs/documents/product-information/vistide-epar-product-information_cs.pdf)

dansk (DA) (842.26 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/da/documents/product-information/vistide-epar-product-information_da.pdf)

Deutsch (DE) (333.47 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/de/documents/product-information/vistide-epar-product-information_de.pdf)

eesti keel (ET) (856.23 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/et/documents/product-information/vistide-epar-product-information_et.pdf)

ελληνικά (EL) (1.66 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/el/documents/product-information/vistide-epar-product-information_el.pdf)

français (FR) (326.81 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/fr/documents/product-information/vistide-epar-product-information_fr.pdf)

íslenska (IS) (767.64 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/is/documents/product-information/vistide-epar-product-information_is.pdf)

italiano (IT) (845.86 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/it/documents/product-information/vistide-epar-product-information_it.pdf)

latviešu valoda (LV) (1.39 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/lv/documents/product-information/vistide-epar-product-information_lv.pdf)

lietuvių kalba (LT) (998.8 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/lt/documents/product-information/vistide-epar-product-information_lt.pdf)

magyar (HU) (1.22 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/hu/documents/product-information/vistide-epar-product-information_hu.pdf)

Malti (MT) (1.34 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/mt/documents/product-information/vistide-epar-product-information_mt.pdf)

Nederlands (NL) (859.74 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/nl/documents/product-information/vistide-epar-product-information_nl.pdf)

norsk (NO) (758.64 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/no/documents/product-information/vistide-epar-product-information_no.pdf)

polski (PL) (1.36 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/pl/documents/product-information/vistide-epar-product-information_pl.pdf)

português (PT) (853.79 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/pt/documents/product-information/vistide-epar-product-information_pt.pdf)

română (RO) (992.29 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/ro/documents/product-information/vistide-epar-product-information_ro.pdf)

slovenčina (SK) (1.3 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/sk/documents/product-information/vistide-epar-product-information_sk.pdf)

slovenščina (SL) (1.25 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/sl/documents/product-information/vistide-epar-product-information_sl.pdf)

Suomi (FI) (302.19 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/fi/documents/product-information/vistide-epar-product-information_fi.pdf)

svenska (SV) (852.21 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

19/01/2015

[View](/sv/documents/product-information/vistide-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0034 22/08/2014

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vistide : EPAR - All Authorised presentations

English (EN) (466.42 KB - PDF)

**First published:** 31/08/2006

**Last updated:** 19/01/2015

[View](/en/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_en.pdf)

[Other languages (22)](#file-language-dropdown-833)

български (BG) (475.83 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/bg/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_bg.pdf)

español (ES) (475.88 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/es/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_es.pdf)

čeština (CS) (525.05 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/cs/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (15.54 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/da/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (475.47 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/de/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (476.17 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/et/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (533.86 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/el/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_el.pdf)

français (FR) (475.8 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/fr/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (475.64 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/is/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_is.pdf)

italiano (IT) (475.96 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/it/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (531.39 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/lv/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (510.3 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/lt/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (504.02 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/hu/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (508.21 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/mt/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (475.97 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/nl/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (475.94 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/no/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_no.pdf)

polski (PL) (529.64 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/pl/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_pl.pdf)

português (PT) (475.95 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/pt/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_pt.pdf)

slovenčina (SK) (521.04 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/sk/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (487.91 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/sl/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (480.44 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/fi/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (476.44 KB - PDF)

**First published:**

31/08/2006

**Last updated:**

19/01/2015

[View](/sv/documents/all-authorised-presentations/vistide-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vistide Active substance cidofovir International non-proprietary name (INN) or common name cidofovir Therapeutic area (MeSH) Cytomegalovirus Retinitis Anatomical therapeutic chemical (ATC) code J05AB12

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable.

## Authorisation details

EMA product number EMEA/H/C/000121 Marketing authorisation holder

Gilead Sciences International Limited

Cambridge

Marketing authorisation issued 23/04/1997 Withdrawal of marketing authorisation 22/08/2014 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vistide : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (645.02 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 19/01/2015

[View](/en/documents/procedural-steps-after/vistide-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Vistide-H-C-121-A20-35 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/303411/2012

English (EN) (572.91 KB - PDF)

**First published:** 09/08/2012

**Last updated:** 19/01/2015

[View](/en/documents/variation-report/vistide-h-c-121-a20-35-epar-assessment-report-article-20_en.pdf)

Vistide : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (554.98 KB - PDF)

**First published:** 17/11/2005

**Last updated:** 19/01/2015

[View](/en/documents/steps-after-cutoff/vistide-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Vistide : EPAR - Procedural steps taken before authorisation

English (EN) (538.59 KB - PDF)

**First published:** 17/11/2005

**Last updated:** 19/01/2015

[View](/en/documents/procedural-steps/vistide-epar-procedural-steps-taken-authorisation_en.pdf)

Vistide : EPAR - Scientific Discussion

English (EN) (691.28 KB - PDF)

**First published:** 17/11/2005

**Last updated:** 19/01/2015

[View](/en/documents/scientific-discussion/vistide-epar-scientific-discussion_en.pdf)

#### News on Vistide

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-february-2012) 17/02/2012

[European Medicines Agency gives final recommendations for 12 centrally authorised medicines manufactured at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-final-recommendations-12-centrally-authorised-medicines-manufactured-ben-venue-laboratories) 16/02/2012

[European Medicines Agency recommends precautionary recall of remaining batch of Vistide manufactured at Ben Venue Laboratories](/en/news/european-medicines-agency-recommends-precautionary-recall-remaining-batch-vistide-manufactured-ben-venue-laboratories) 13/12/2011

[European Medicines Agency gives further interim recommendations on dealing with shortcomings in quality assurance at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-further-interim-recommendations-dealing-shortcomings-quality-assurance-ben-venue-laboratories) 09/12/2011

[European Medicines Agency gives interim recommendations to deal with shortcomings in quality assurance at Ben Venue Laboratories](/en/news/european-medicines-agency-gives-interim-recommendations-deal-shortcomings-quality-assurance-ben-venue-laboratories) 22/11/2011

#### More information on Vistide

Final recommendations on 12 centrally authorised medicines manufactured at Ben Venue Laboratories

Reference Number: EMA/106872/2012

English (EN) (188.14 KB - PDF)

**First published:** 16/02/2012

**Last updated:** 22/02/2012

[View](/en/documents/medicine-qa/final-recommendations-12-centrally-authorised-medicines-manufactured-ben-venue-laboratories_en.pdf)

Questions and answers on shortcomings in quality assurance at Ben Venue Laboratories

Reference Number: EMA/946321/2011

English (EN) (71.91 KB - PDF)

**First published:** 13/12/2011

**Last updated:** 13/12/2011

[View](/en/documents/medicine-qa/questions-and-answers-shortcomings-quality-assurance-ben-venue-laboratories_en.pdf)

Questions and answers on the shortage of Vistide

Reference Number: EMA/101129/2013

English (EN) (70.29 KB - PDF)

**First published:** 28/02/2013

**Last updated:** 28/02/2013

[View](/en/documents/medicine-qa/questions-and-answers-shortage-vistide_en.pdf)

**This page was last updated on** 19/01/2015

## Share this page

[Back to top](#main-content)